| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
4,718 |
3,804 |
$310K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
4,492 |
3,653 |
$201K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
4,556 |
3,717 |
$180K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
3,813 |
3,157 |
$64K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
112 |
102 |
$41K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
908 |
805 |
$32K |
| 86328 |
|
39 |
36 |
$2K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
19 |
12 |
$205.24 |